John Tunnell, AUD in Fairmont, MN - Medicare Audiologist Provider

John Tunnell, AUD is a medicare enrolled "Audiologist" provider in Fairmont, Minnesota. His current practice location is 800 Medical Center Dr, Fairmont, Minnesota. You can reach out to his office (for appointments etc.) via phone at (507) 238-8555.

John Tunnell is licensed to practice in Minnesota (license number 7328) and he also participates in the medicare program. He does not accept medicare assignments directly but he may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. His NPI Number is 1629055272.

Contact Information

	John Tunnell, AUD
	800 Medical Center Dr, Fairmont, MN 56031-4575
	(507) 238-8555
	Not Available

Healthcare Provider's Profile

Full Name	John Tunnell
Gender	Male
Speciality	Audiologist
Location	800 Medical Center Dr, Fairmont, Minnesota
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1629055272
Provider Enumeration Date: 12/26/2005
Last Update Date: 11/16/2023

Medicare PECOS Information:

PECOS PAC ID: 0648235176
Enrollment ID: I20041124000196

Medical Identifiers

Medical identifiers for John Tunnell such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1629055272	NPI	-	NPPES
551179	Medicaid	IA
546K3TU	Medicaid	MN
1216789	Other	MN	ARAZ
MH9041030107	Other	MN	PREFERREDONE
45-00242	Other	MN	MEDICA
546K3TU	Other	MN	BLUE CROSS
A067	Other	MN	CHAMPUS
56033200	Medicaid	MN
HP51396	Other	MN	HEALTHPARTNERS

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
231H00000X	Audiologist	7328 (Minnesota)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. John Tunnell is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
John Tunnell, AUD 800 Medical Center Dr, Po Box 800, Fairmont, MN 56031-4575 Ph: (507) 238-8555	John Tunnell, AUD 800 Medical Center Dr, Fairmont, MN 56031-4575 Ph: (507) 238-8555

News Archive

South Carolina optometrists provide eye, vision assessments for infants through InfantSEE

Due to the overwhelming number of children with eye and vision problems across the United States, South Carolina optometrists are devoting appointments to no-cost, comprehensive eye and vision assessments for infants between six to 12 months of age through InfantSEE.

Researchers develop first sensor that can identify IBD and distinguish between two subtypes

Researchers have developed the first sensor capable of objectively identifying inflammatory bowel disease (IBD) and distinguishing between its two subtypes.

New approach to platelet replacement therapy for thrombocytopenia

Platelets are cells in the blood that have a key role in stopping bleeding. Thrombocytopenia is the medical term used to describe the presence of abnormally low numbers of platelets in the blood. Platelet transfusion is used to treat several causes of thrombocytopenia, but there is a shortage of donors. Mortimer Poncz and colleagues, at Children's Hospital of Philadelphia, working with mice, have now identified a potential new approach to platelet replacement therapy that circumvents the problem of donor shortage.

Innovative procedure may improve outcomes in people with keratoconus

An innovative procedure may improve outcomes in people with a degenerative eye disease, suggest five-year results from a study presented at AAO 2016, the 120th annual meeting of the American Academy of Ophthalmology.

Micromet to present new data from its blinatumomab Phase 1 trial at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a poster with new data from its ongoing phase 1 clinical trial of its product candidate blinatumomab in patients with non-Hodgkin's lymphoma (NHL) at the 51ST Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

John Tunnell, AUD - Medicare Audiologist in Fairmont, MN